Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

This study looks at whether adding cadonilimab (an immunotherapy drug) to standard treatment can improve outcomes for people with locally advanced colorectal cancer that has a specific molecular marker called MSI-H or dMMR — meaning the cancer cells have a defect in their DNA repair system, which can make them respond better to immunotherapy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with colon or rectal cancer that is locally advanced (spread to nearby lymph nodes or through the bowel wall) - Your tumor has been confirmed as MSI-H or dMMR by lab tests - You have not received any prior treatment for this cancer - You are in good health (ECOG 0–1) **You may NOT be eligible if...** - You have already received treatment for this cancer - Your blood counts, liver, or kidney function are not within acceptable ranges - You have active autoimmune disease or are on long-term steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.